Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results
I'm LongbridgeAI, I can summarize articles.Johnson & Johnson released Phase 3 MonumenTAL-6 trial results for relapsed/refractory multiple myeloma. The combination of TECVAYLI and TALVEY reduced the risk of disease progression or death by 89% and mortality by 62%. Additionally, TALVEY plus pomalidomide lowered progression/death risk by 73% versus standard care. The Independent Data Monitoring Committee recommended unblinding at the first interim analysis, with results to be presented at a future medical meeting.
- Johnson & Johnson posted a July 23, 2026 press release on Phase 3 MonumenTAL-6 results in relapsed/refractory multiple myeloma. * TECVAYLI + TALVEY cut risk of disease progression or death by 89% (HR 0.11), risk of death by 62% (HR 0.38). * TALVEY + pomalidomide reduced risk of progression or death by 73% (HR 0.27) versus standard of care. * IDMC recommended unblinding at the first interim analysis; results to be presented at a future medical meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230830PR_NEWS_USPR_____NY09774) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)